Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH
NCT05140525 · Dr Sudarshan Rajagopal · PHASE3 · terminated · last registry update 2026-09-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor Requested” | – | Registry record, Dr Sudarshan Rajagopal |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EDNRB within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-07-06Results posted on the registry: United Therapeutics, Ralinepag + Placebo (NCT04084678)
- 2026-07-06Also stopped (terminated): United Therapeutics, Ralinepag + Placebo (NCT04084678)
- 2026-06-15Also stopped (suspended): City of Hope Medical Center, Bosentan + Gemcitabine (NCT04158635)
- 2026-06-09Phase 3 first posted: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., Aprocitentan tablets(SYH9108) + Placebo (NCT07635914)
- 2026-03-30Results posted on the registry: Boehringer Ingelheim, BI 425809 + Bosentan (NCT05723874)
- 2025-11-24Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Tadalafil + Ambrisentan (NCT07245680)
- 2025-10-21Results posted on the registry: Janssen Pharmaceutical K.K., Macitentan (NCT05167825)
- 2025-09-16Results posted on the registry: PharmaMar, Lurbinectedin + Bosentan (NCT05072106)
- 2025-09-12Results posted on the registry: Actelion, Macitentan (NCT02932410)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision